Related Experiment Video

Updated: Jun 19, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

Peter C Taylor1, Marc Feldmann

  • 1Kennedy Institute of Rheumatology Division, Imperial College, London, UK. peter.c.taylor@imperial.ac.uk

Nature Reviews. Rheumatology
|October 3, 2009
PubMed

Insights

Tumor necrosis factor (TNF) blockade is a cornerstone therapy for rheumatoid arthritis (RA). New strategies targeting TNF may offer enhanced clinical responses for patients with RA.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • High levels of tumor necrosis factor (TNF) in rheumatoid joint tissue drive inflammation and destruction in rheumatoid arthritis (RA).
  • Anti-TNF biologic therapies have been a mainstay in RA treatment for nearly a decade.
  • Interleukin (IL)-6 and IL-1 are other validated cytokine targets in RA, with several agents under investigation.

Purpose of the Study:

  • To review the current understanding and therapeutic application of anti-TNF agents in rheumatoid arthritis.
  • To compare the efficacy of TNF blockade with other cytokine-targeted therapies (IL-6, IL-1) in RA.
  • To explore potential future advancements in TNF-targeted therapies for RA.

Main Methods:

  • Review of existing literature on TNF, IL-6, and IL-1 as therapeutic targets in RA.
  • Analysis of clinical outcomes and therapeutic benefits of anti-TNF agents.
  • Discussion of emerging strategies for TNF signaling blockade.

Main Results:

  • TNF remains a primary target for first-line biologic therapy in RA.
  • Biologic inhibition of IL-6 or IL-1 does not show superior outcomes to TNF blockade in active RA patients on nonbiologic DMARDs.
  • Novel approaches to TNF blockade may yield greater clinical responses than current therapies.

Conclusions:

  • TNF blockade is an established and effective treatment for rheumatoid arthritis.
  • Current evidence does not support IL-6 or IL-1 blockade as superior to TNF blockade for first-line biologic therapy in RA.
  • Future research into advanced TNF-targeting strategies holds promise for improved RA management.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...